{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-016947","form_type":"8-K","ticker":"RNXT","cik":"0001574094","company_name":"RenovoRx, Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.470175+00:00","generated_at":"2026-06-15T01:09:05.328676+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"RenovoRx Q1 2023 net loss $3.3M; Phase III data shows 60% survival benefit","bullets":["Cash and equivalents were $3.7M at March 31, 2023; net loss $3.3M vs $3.0M in Q1 2022.","Phase III TIGeR-PaC interim analysis: 60% survival benefit, >65% reduction in side effects vs systemic chemo.","Closed $5M registered direct offering subsequent to quarter end.","Appointed Robert J. Spiegel (former CMO of Schering-Plough) to Board; Leesa Gentry as SVP Clinical Operations.","Issued 8th U.S. patent extending RenovoTAMP therapy platform IP coverage."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-016947","json":"https://secwatch.observer/filing/0001493152-23-016947.json","markdown":"https://secwatch.observer/filing/0001493152-23-016947.md","text":"https://secwatch.observer/filing/0001493152-23-016947.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574094/000149315223016947/0001493152-23-016947-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574094/000149315223016947/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:09:05.328676+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"44cb3072d57414caef8c631152dfb69d8d56b7ae","claim":"RenovoRx, Inc. reported the first quarter ended March 31, 2023 results: net income $3.3 million.","evidence_excerpt":"RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of cancers, today announced financial results for the first quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1574094/000149315223016947/0001493152-23-016947-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Net income","value":"$3.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}